Roche Signs an Exclusive Worldwide Option and License Agreement with Vividion Focusing on Novel E3 Ligases
Shots:
- Vividion to receive $135M upfront in cash and is eligible to receive billion dollars preclinical- development and commercial milestones along with royalties on sales of commercialized products resulting from the collaboration
- Vividion will be responsible for early drug discovery and pre-clinical development for selected programs and has the right to conduct clinical development up to POC with the option to share development costs along with profits and losses with Roche
- Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3 ligases along with the range of oncology and immunology therapeutic targets and has the exclusive right to license resulting compounds at different stages of development
Click here to read full press release/ article
Ref: PRNewswire | Image: Roche
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com